title: Intramedullary spinal cord germinoma--2 case reports.
abstract: BACKGROUND
  Primary intramedullary spinal cord germinoma is very rare. We encountered 2 patients with primary intramedullary spinal cord germinoma. We describe herein our comprehensive management system for CNS germinoma, including intramedullary spinal cord germinoma, along with a review of the literature. This is the first report to describe successful application of ICE chemotherapy for intramedullary germinoma.
  
  
  METHODS
  A 16-year-old adolescent girl (case 1) experienced lumbago and subsequently noticed gait disturbance that aggravated gradually. On admission, paraparesis and urinary retention were noted. Magnetic resonance imaging demonstrated marked cord swelling between T9 and T12, with slight enhancement in the spinal cord. Astrocytic tumor was initially suspected, and partial removal was performed. However, pathologic examination identified germinoma. Successful treatment with ICE chemotherapy and radiotherapy was implemented, with no evidence of recurrence apparent at 48 months postoperatively. A 34-year-old woman (case 2) presented with paraparesis and sensory disturbance. Magnetic resonance imaging demonstrated cord swelling between T8 and T10, with slight Gd-DTPA enhancement. Because the lesion did not respond to steroid pulse therapy, spinal cord tumor was suspected and biopsy was performed. Pathologic examination verified primary germinoma of the spine. Successful treatment with ICE chemotherapy and radiotherapy was implemented with no exacerbation of neurologic deficits. No evidence of recurrence was apparent at 36 months postoperatively.
  
  
  CONCLUSIONS
  Correct diagnosis of very rare primary intramedullary spinal cord germinoma is important, because these patients can be treated successfully using chemo- and radiotherapy without neurologic deterioration.
authors.affiliation: Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo 060-8636, Japan. tataoya@sirius.ocn.ne.jp
authors.forename: Takeshi
authors.initials: T
authors.lastname: Aoyama
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Hida
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Ishii
authors.forename: Toshitaka
authors.initials: T
authors.lastname: Seki
authors.forename: Jun
authors.initials: J
authors.lastname: Ikeda
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Iwasaki
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000032:analysis / Q000378:metabolism; D005260:Female; D018237:Germinoma / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D019635:Neurosurgical Procedures; D020335:Paraparesis / Q000209:etiology; D011878:Radiotherapy; D013116:Spinal Cord / Q000473:pathology* / Q000503:physiopathology; D013120:Spinal Cord Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D016896:Treatment Outcome; D014555:Urination Disorders / Q000209:etiology
chemical_list: D014408:Biomarkers, Tumor; D018997:Chorionic Gonadotropin, beta Subunit, Human